01—Abstract
Summary
Summary of the 8-K filed December 13, 2024. Cited figures are marked; the original filing is the authoritative source.
Agilent Technologies, Inc. has announced a significant reorganization of its operational structure, effective for financial reporting beginning with the quarter ending January 31, 2025.
The company is shifting to a market-focused, customer-centric strategy, which will be reflected in three newly defined reportable business segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab. This change aims to better align the company's operations with its strategic goals and provide clearer insights into performance across these key areas. This 8-K filing provides investors with selected unaudited historical financial information recast under these new segments.
While this information is being furnished and not formally filed for Section 18 liability, it offers a preview of how Agilent's past performance will be presented moving forward. Investors should note that prior periods will be restated accordingly, enabling a more consistent comparison once the new structure is fully implemented.
02—Key points
Key Highlights
- Agilent Technologies is reorganizing into three new reportable business segments: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab.
- The new structure is driven by a market-focused and customer-centric strategy.
- Financial reporting will reflect the new segments starting with the fiscal quarter ending January 31, 2025.
- Prior financial periods will be recast to align with the new segment structure for consistent historical comparison.
- The filing includes selected unaudited historical financial information under the new segments for fiscal quarters and years dating back to FY2022.
- This information is furnished under Regulation FD and is not deemed 'filed' for Section 18 purposes.
03—Questions
Frequently Asked Questions
What is the primary reason for Agilent's operational reorganization?
Agilent is reorganizing its operational structure to support a market-focused and customer-centric strategy. This aims to better align the company's business operations with its strategic goals and provide more granular insights into performance across key market areas.
When will investors see financial results under the new segment structure?
Financial statements will reflect the new reporting structure beginning with the fiscal quarter ending January 31, 2025. Prior periods will also be recast to allow for historical comparability.
What are the new reportable segments?
The three new reportable segments are: Life Sciences and Diagnostics Markets, Applied Markets, and Agilent CrossLab.
Is the financial information provided in this 8-K considered officially 'filed'?
No, the information contained in this 8-K filing, including the selected financial information, is being furnished under Regulation FD and is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means the company is not subject to the liabilities associated with Section 18 for this disclosed information.
04—Continue